Skip to main content

Table 1 Baseline characteristics for the entire study sample with clinical COPD and the subgroup with verified COPD

From: Validation of the Clinical COPD Questionnaire (CCQ) in primary care

 

Clinical COPD

Verified COPD

(FEV1/FVC < 0.70**)

Subjects n

111

83

Female (%)

65.8

62.7

Age years, mean, (range)

67.1, (42–85)

67.1, (42–85)

Smoking habits (%)

  

   Non-smokers

2.8

1.2

   Ex-smokers

56.9

61.4

   Smokers

40.4

34.9

   Missing data

1.8

2.4

Disease known since, (%)

  

   < 1 yrs

19.8

10.8

   1–5 yrs

37.8

39.8

   > 5 yrs

42.3

49.4

BMI, mean, (range)

24.4, (17–39)

24.2, (17–39)

FEV1/FVC ratio – mean (SD), range

57.8 (14.3), range (26.0–92.6)

52.4 (11.4), range (26.0–69.0)

FEV1, % predicted, mean (SD), range

58.1 (20.2), range (14.8–111.5)

52.5 (17.9), range (14.8–102.6)

Severity classification, (%) FEV1 (post bronch. dil.)

  

   FEV1 ≥ 80% predicted

11.0

7.3

   50% ≤ FEV1 < 80% predicted

52.3

46.3

   30% ≤ FEV1 < 50% predicted

30.3

37.8

   FEV1 < 30% predicted

6.4

8.5

Medication visit 1 (visit 2)#

  

   - Only SABA or ipratropium as needed (%)

4.5 (6.5)

6.1 (6.3)

   - Ipratropium, tiotropium, LABA or SABA as regular medication (%)

28.2 (26.2)

26.8 (26.6)

- Ipratropium, tiotropium, LABA or SABA and ICS

as regular medication (%)

50.0 (50.5

54.9 (55.7)

   - ICS without any regular brochodilators (%)

3.6 (6.5)

2.4 (5.1)

   - No medication (%)

13.6 (10.3)

9.8 (6.3)

   - Missing data (n)

1 (4)

1 (4)

  1. *Including four patients with missing data for the ratio FEV1/FVC. ** At visit 1.
  2. # Medication during the week preceding the two visits.
  3. BMI = body mass index, FEV1 = forced expiratory volume in one second, SABA= short-acting beta 2-agonist, LABA = long-acting beta 2-agonist, ICS = inhaled corticosteroids.